Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2024HemaSphereOpen Access

Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab

View Full Paper
Ask AI
Bookmark
Share

Authors

AKArnon P. KaterDutch Cancer SocietyBEBarbara EichhorstTH Köln - University of Applied SciencesCOCarolyn OwenUniversity of Calgary

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kater et al. (2024) studied this question.

synapsesocial.com/papers/68e5dfdcb6db643587574637https://doi.org/10.1002/hem3.146
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia2019 · 19 citations
  2. 2Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure−Response Analysis2019 · 12 citations
  3. 3Kinetics of T‐cell subset reconstitution following treatment with bendamustine and rituximab for low‐grade lymphoproliferative disease: a population‐based analysis2018 · 57 citations
  4. 4Infectious complications of purine analog therapy2001 · 57 citations
  5. 5Perturbation of the normal immune system in patients with CLL2015 · 399 citations